254 related articles for article (PubMed ID: 7698167)
1. Cardiovascular effects of YM099, a novel K+ channel opener, in anesthetized and conscious dogs.
Uchida W; Hirano Y; Taguchi T; Masuda N; Shirai Y; Satoh N; Takenaka T
Eur J Pharmacol; 1994 Nov; 264(3):285-93. PubMed ID: 7698167
[TBL] [Abstract][Full Text] [Related]
2. Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta.
Uchida W; Hirano Y; Shirai Y; Taguchi T; Masuda N; Shibasaki K; Hirano S; Matsumoto Y; Tsuzuki R; Yanagisawa I
Arch Int Pharmacodyn Ther; 1994; 327(3):330-43. PubMed ID: 7848015
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of vasodilator effects of the potassium channel openers NIP-121 and levcromakalim in dogs and rats.
Yamashita T; Masuda Y; Kawamura N; Fujikura N; Tanaka S
Jpn J Pharmacol; 1995 Jun; 68(2):145-52. PubMed ID: 7563971
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
[TBL] [Abstract][Full Text] [Related]
5. Effects of cromakalim and pinacidil on large epicardial and small coronary arteries in conscious dogs.
Giudicelli JF; la Rochelle CD; Berdeaux A
J Pharmacol Exp Ther; 1990 Nov; 255(2):836-42. PubMed ID: 2173761
[TBL] [Abstract][Full Text] [Related]
6. Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide.
Imagawa J; Akima M; Nabata H; Taira N
J Cardiovasc Pharmacol; 1992 Jan; 19(1):108-14. PubMed ID: 1375676
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic profiles of YM934, a novel potassium channel opener.
Uchida W; Masuda N; Taguchi T; Shibasaki K; Shirai Y; Asano M; Matsumoto Y; Tsuzuki R; Fujikura T; Takenaka T
J Cardiovasc Pharmacol; 1994 Feb; 23(2):180-7. PubMed ID: 7511745
[TBL] [Abstract][Full Text] [Related]
8. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Yoneyama F; Satoh K; Taira N
Cardiovasc Drugs Ther; 1990 Aug; 4(4):1119-26. PubMed ID: 2150593
[TBL] [Abstract][Full Text] [Related]
9. Regional blood flow and cardiac responses to hydralazine.
Spokas EG; Wang HH
J Pharmacol Exp Ther; 1980 Feb; 212(2):294-303. PubMed ID: 7351643
[No Abstract] [Full Text] [Related]
10. Effect of an ATP sensitive potassium channel opener, levcromakalim, on coronary arterial microvessels in the beating canine heart.
Sato K; Kanatsuka H; Sekiguchi N; Akai K; Wang Y; Sugimura A; Kumagai T; Komaru T; Shirato K
Cardiovasc Res; 1994 Dec; 28(12):1780-6. PubMed ID: 7867030
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
D'Alonzo AJ; Grover GJ; Darbenzio RB; Sewter JC; Hess TA; Dzwonczyk S; Sleph PG
Pharmacology; 1996 Feb; 52(2):101-12. PubMed ID: 8851631
[TBL] [Abstract][Full Text] [Related]
13. Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs.
Hirata Y; Aisaka K
J Cardiovasc Pharmacol; 1997 Mar; 29(3):397-405. PubMed ID: 9125679
[TBL] [Abstract][Full Text] [Related]
14. Effects of a K+ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine.
Shen YT; Vatner SF
J Pharmacol Exp Ther; 1993 May; 265(2):1026-37. PubMed ID: 8496801
[TBL] [Abstract][Full Text] [Related]
15. Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K+ATP channels.
Minkes RK; Kvamme P; Higuera TR; Nossaman BD; Kadowitz PJ
Am J Physiol; 1991 Mar; 260(3 Pt 2):H957-66. PubMed ID: 1825747
[TBL] [Abstract][Full Text] [Related]
16. Coronary and systemic hemodynamic effects of the putative nitric oxide donor, FK 409, in comparison with nitroglycerin in conscious and anesthetized dogs.
Drieu la Rochelle C; Lainée P; Grosset A; O'Connor SE
J Cardiovasc Pharmacol; 1995 Oct; 26(4):555-63. PubMed ID: 8569215
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs.
Nakae I; Quan L; Hashimoto K; Sugimoto Y; Tsutamoto T; Kinoshita M
Cardiovasc Drugs Ther; 1994 Feb; 8(1):137-45. PubMed ID: 8086324
[TBL] [Abstract][Full Text] [Related]
18. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
19. Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine.
Izumi H; Jinno Y; Kaneta S; Tanaka Y; Okada Y; Izawa T; Ogawa N
J Cardiovasc Pharmacol; 1995 Aug; 26(2):189-97. PubMed ID: 7475042
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of nitrovasodilators, K(+)-channel openers, and nicorandil on large and small coronary arteries in conscious dogs.
Berdeaux A; Drieu la Rochelle C; Richard V; Giudicelli JF
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S17-21. PubMed ID: 1282171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
